Mumbai, Pharma major Glenmark Pharmaceuticals Inc., USA has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Axitinib Tablets, 1 mg and 5 mg, the generic version of InlytaTablets, 1 mg and 5 mg, of PF Prism C.V. According to IQVIATM sales, data for the 12 month period ending October 2020, the Inlyta Tablets, 1mg and 5 mg market achieved annual sales of approximately USD518.8 million., company release said. Glenmark’s current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings,